177Lu-PSMA-617 extends progression-free survival in taxane-naive mCRPC

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology Pub Date : 2024-11-11 DOI:10.1038/s41585-024-00970-z

Maria Chiara Masone

引用次数: 0

查看原文本刊更多论文

177Lu-PSMA-617可延长抗类固醇药物无效mCRPC患者的无进展生存期

我们开展了一项新的III期随机对照试验，以评估177Lu-PSMA-617对他汀类药物无效的转移性抗性前列腺癌（mCRPC）患者的疗效。共有468名PSMA+ mCRPC患者在接受雄激素受体通路抑制剂（ARPI）治疗后出现疾病进展，他们被随机分配接受177Lu-PSMA-617或另一种ARPI治疗。与更换ARPI相比，177Lu-PSMA-617治疗可改善中位放射学无进展生存期（PFS）（11.60个月（95% CI 9.30-14.19）对5.59个月（95% CI 4.21-5.95）），且安全性良好。这些结果表明，177Lu-PSMA-617可延长放射学PFS，可作为考虑更换ARPI的患者的有效替代治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Urology 医学-泌尿学与肾脏学

CiteScore

12.50

自引率

2.60%

发文量

123

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline. The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals. Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.